French_Vibe
Nov 10, 11:40 AM
$HALO I checked the last presentation, and there is no mention of Petosemtamab. We can expect around 2% of royalties on the SC form (following the deal with Merus, acquired by
$GMAB), and the peak sales of Peto are conservatively estimated between
$4-5B (probably between 2030-2035). So it could add
$80M-
$100M of royalties to Halozyme.
0 replies